RATIONALE AND OBJECTIVE: Because of the important role of dopamine in neurotransmission, it would be useful to be able to image brain dopamine receptor-mediated signal transduction in animals and humans. Administering the D1-D2 receptor agonist apomorphine may allow us to do this, as the D2-like receptor is reported to be coupled to cytosolic phospholipase A2 activation and arachidonic acid (AA) release from membrane phospholipid. METHODS: Unanesthetized adult rats were given intraperitoneally apomorphine (0.5 mg/kg) or saline, with or without pretreatment with 6 mg/kg intravenous raclopride, a D2/D3 receptor antagonist. [1-14C]AA was injected intravenously, then AA incorporation coefficients k*--brain radioactivity divided by integrated plasma radioactivity--markers of AA signaling, were measured using quantitative autoradiography in 62 brain regions. RESULTS: Apomorphine significantly elevated k* in 26 brain regions, including the frontal cortex, motor and somatosensory cortex, caudate-putamen, thalamic nuclei, and nucleus accumbens. Raclopride alone did not change baseline values of k*, but raclopride pretreatment prevented the apomorphine-induced increments in k*. CONCLUSIONS: A mixed D1-D2 receptor agonist, apomorphine, increased the AA signal by activating only D2-like receptors in brain circuits containing regions with high D2-like receptor densities. Thus, apomorphine might be used with positron emission tomography to image brain D2-like receptor-mediated AA signaling in humans in health and disease.
RATIONALE AND OBJECTIVE: Because of the important role of dopamine in neurotransmission, it would be useful to be able to image brain dopamine receptor-mediated signal transduction in animals and humans. Administering the D1-D2 receptor agonist apomorphine may allow us to do this, as the D2-like receptor is reported to be coupled to cytosolic phospholipase A2 activation and arachidonic acid (AA) release from membrane phospholipid. METHODS: Unanesthetized adult rats were given intraperitoneally apomorphine (0.5 mg/kg) or saline, with or without pretreatment with 6 mg/kg intravenous raclopride, a D2/D3 receptor antagonist. [1-14C]AA was injected intravenously, then AA incorporation coefficients k*--brain radioactivity divided by integrated plasma radioactivity--markers of AA signaling, were measured using quantitative autoradiography in 62 brain regions. RESULTS:Apomorphine significantly elevated k* in 26 brain regions, including the frontal cortex, motor and somatosensory cortex, caudate-putamen, thalamic nuclei, and nucleus accumbens. Raclopride alone did not change baseline values of k*, but raclopride pretreatment prevented the apomorphine-induced increments in k*. CONCLUSIONS: A mixed D1-D2 receptor agonist, apomorphine, increased the AA signal by activating only D2-like receptors in brain circuits containing regions with high D2-like receptor densities. Thus, apomorphine might be used with positron emission tomography to image brain D2-like receptor-mediated AA signaling in humans in health and disease.
Authors: Lara A Hosey; Jennifer L W Thompson; Leonard Verhagen Metman; Pepyn van den Munckhof; Allen R Braun Journal: Clin Neuropharmacol Date: 2005 Jan-Feb Impact factor: 1.592
Authors: Abesh K Bhattacharjee; Lisa Chang; Laura White; Richard P Bazinet; Stanley I Rapoport Journal: J Cereb Blood Flow Metab Date: 2006-03-01 Impact factor: 6.200
Authors: A I Levey; S M Hersch; D B Rye; R K Sunahara; H B Niznik; C A Kitt; D L Price; R Maggio; M R Brann; B J Ciliax Journal: Proc Natl Acad Sci U S A Date: 1993-10-01 Impact factor: 11.205
Authors: Samuel P Lee; Christopher H So; Asim J Rashid; George Varghese; Regina Cheng; A José Lança; Brian F O'Dowd; Susan R George Journal: J Biol Chem Date: 2004-05-24 Impact factor: 5.157
Authors: Madhav Thambisetty; Kathy A Gallardo; Jeih-San Liow; Lori L Beason-Held; John C Umhau; Abesh K Bhattacharjee; Margaret Der; Peter Herscovitch; Judith L Rapoport; Stanley I Rapoport Journal: J Cereb Blood Flow Metab Date: 2011-12-14 Impact factor: 6.200
Authors: Epolia Ramadan; Lisa Chang; Mei Chen; Kaizong Ma; F Scott Hall; George R Uhl; Stanley I Rapoport; Mireille Basselin Journal: Int J Neurosci Date: 2012-03-26 Impact factor: 2.292
Authors: Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport Journal: Neuropharmacology Date: 2011-08-03 Impact factor: 5.250
Authors: Hyung-Wook Kim; Yewon Cheon; Hiren R Modi; Stanley I Rapoport; Jagadeesh S Rao Journal: Psychopharmacology (Berl) Date: 2012-03-14 Impact factor: 4.530